



Learn more about RSV adult vaccine implementation with GSK



Saturday, March 23 | 12:00-1:00pm | Exhibit Hall – Theater 2

Navigating RSV in Adults: Insights into Disease and Vaccination

Of the estimated 8.4 million RSV vaccines administered to adults ≥ 60 years old in 2023, >97% were in the pharmacy. Join us for a panel discussion focusing on the burden of RSV disease in adults, risk factors for severe RSV disease, and public health implications of RSV. The panel experts will discuss considerations for RSV vaccine implementation in the adult population following the ACIP's recommendation that adults aged ≥ 60 years may receive a single dose of an RSV vaccine using shared clinical decision-making. The discussion will focus on the role of the pharmacist in RSV adult immunization.

A Presentation Theater held in conjunction with APhA2024.



Theresa Tolle, BPharm, FAPhA

Speaker

Owner and Chief Pharmacist of Bay Street Pharmacy



Christina Madison, PharmD, FCCP, AAHIVP

Speaker

TedX Speaker, Founder and CEO of The Public Health Pharmacist®, PLLC



Barbara Yawn, MD, MSc, MSPH, FAAFP

Speaker

Adjunct Professor, Department of Family and Community Health
University of Minnesota



Megan Riley, PhD

Facilitator

Medical Director, RSV Vaccines
US Medical Affairs, GSK

GSK

Trademarks owned or licensed by GSK

PSE-US-2562

Centers for Disease Control and Prevention, January 16, 2024.

<https://www.cdc.gov/vaccines/imz-managers/coverage/rsvaxview/adult-vaccinations-administered.html>

Visit GSK Medical Booth #401

**& scan here to learn more
about RSV disease in
your patients**

